Medipost participated in ‘BIO KOREA 5 (Bio Korea 10)’, which opened on May 12th (Wed) and was held at COEX in Seoul for 3 days until May 2023th (Friday), and introduced the CDMO service for consignment development and production of cell therapy products. .
Established in 2000, Medipost aims to be the ‘global number one stem cell company’ that develops stem cell treatments from its founding philosophy to its current vision and provides cutting-edge biopharmaceuticals that provide new hope to patients with incurable diseases.
Medipost has been leading the entry of stem cell treatments into the biopharmaceutical market with the approval of the allogeneic stem cell treatment Cartistem, and as a domestic cord blood bank operator, even in a situation where the birth rate is rapidly decreasing, we are enhancing and recognizing the value of cord blood as a valuable personalized bio resource. Market expansion has been achieved through change.
The CDMO service for consignment development and production of cell therapy products introduced at this exhibition was cited as an advantage in that it is possible to enter clinical trials and commercialization within a short period of time. We have local GMP facilities in Korea and North America that comply with the latest GMP regulations, and we provide the best service for each item through a package of advanced human resources with extensive experience in stem cell treatment development, development, manufacturing, quality testing, and licensing support for cutting-edge biopharmaceuticals. .
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th anniversary this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. BIO KOREA, which has been striving to improve the global status and sustainable growth of the Korean health industry since 2006, is solidifying its position as Korea’s representative biohealth international convention with the participation of world-class scholars and business experts every year. BIO KOREA 2023, in collaboration with companies related to the health industry such as domestic and foreign bio, pharmaceuticals, medical devices, cosmetics, and food, as well as interested companies and institutions such as consulting, academia, and related organizations, will be held through various programs such as conferences, business partnering, exhibitions, and investment fairs. It goes on.
→ Go to the BIO KOREA 2023 news special page
